BridgeBio Oncology Extends Cash Runway Into 2029

The Tip Desk · November 10, 2026 · 3 min read

Cash, cash equivalents and marketable securities stood at $315.3 million as of September 30, 2026, as the company reported a $34.2 million net loss for the third quarter.

BridgeBio Oncology Therapeutics, Inc. (BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, said cash, cash equivalents and marketable securities of $315.3 million as of September 30, 2026 is expected to fund operations into 2029, a later horizon than the into-2028 runway it cited with the June 30 cash position of $344.1 million.

The company reported a net loss of $34.2 million, or $0.43 a share, for the third quarter of 2026, compared with a $44.8 million loss, or $1.03 a share, a year earlier. Total operating expenses were $37.5 million.

Research and development expenses were $29.6 million in the third quarter of 2026, down from $49.2 million in the second quarter of 2026. General and administrative expenses were $7.9 million, compared with $14.1 million a year earlier; the company said the year-ago figure included a $7.8 million charge related to common stock issuable to BridgeBio Pharma, partially offset by an increase in legal and other business expenses.

Chief Executive Officer Pedro J. Beltran said the third quarter was an important period as the company reported updated clinical data for BBO-8520 and delineated its strategic focus, and that with a strong balance sheet, multiple data catalysts expected through mid-2027, and cash runway into 2029, BBOT is well positioned to advance differentiated therapies for patients with KRAS-driven cancers.

In September 2026, BBOT announced new data from the ongoing ONKORAS-101 Phase 1 study. BBO-8520 in combination with pembrolizumab in KRASG12C inhibitor-experienced non-small cell lung cancer patients showed an objective response rate of 75% at the 500 mg once-daily dose level and 53% across all dose levels (N=17). Adverse events were primarily gastrointestinal-related, and a favorable liver safety profile was observed. The company said the data position it to address a new G12Ci-experienced patient population created by G12C OFF-only inhibitors in combination with pembrolizumab in first-line KRASG12C-positive NSCLC.

BBO-8520 monotherapy in second-line and later KRASG12C inhibitor-naïve NSCLC showed an ORR of 63% (26/41) and a disease control rate of 100% (41/41). Among 28 patients eligible for a six-month follow-up, 75% (21/28) remained on treatment beyond six months. The safety profile was tolerable and manageable, with no grade 3 or higher liver enzyme elevations.

BBOT initiated dosing of BBO-11818 in combination with BBO-10203 as well as in combination with cetuximab in colorectal cancer and pancreatic ductal adenocarcinoma. Combination cohorts for BBO-11818 and BBO-10203 are enrolling in KRAS-mutant CRC and PDAC. Monotherapy data updates for both BBO-11818 and BBO-10203 are expected in the fourth quarter of 2026.

The company described BBO-8520 as an orally bioavailable small molecule direct inhibitor targeting both the ON and OFF states of KRASG12C, BBO-11818 as a pan-KRAS inhibitor targeting KRASG12D/V in both ON and OFF states, and BBO-10203 as a small molecule designed to block the physical interaction between RAS and PI3Kα. It said the portfolio is designed to achieve concurrent suppression of MAPK and PI3Kα pathways through a wholly-owned internal combination strategy.

Weighted-average shares used in computing net loss per share were 80.2 million for the three months ended September 30, 2026. Interest income was $3.3 million for the quarter.